Engineering Lipid Nanoparticles Beyond ApoE-Mediated Liver Tropism: Design Strategies for Extrahepatic and Organ-Selective Delivery
- 1Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Sciences, Mayo Clinic, Jacksonville, FL 32224, USA
- 2College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33314, USA
- 3Texas A&M Drug Discovery Center and Department of Chemistry, College of Arts and Sciences, Texas A&M University, College Station, TX 77843, USA
Abstract
Lipid nanoparticles (LNPs) have evolved into a significant delivery technology for nucleic acid therapies, including messenger RNA (mRNA), small interfering RNA (siRNA), and genome editing tools. Although LNPs have demonstrated therapeutic success, they display strong tropism to the liver when systemically delivered, thus restricting their use for targeted delivery to extrahepatic organs. The major factor responsible for the liver targeting of LNPs is the binding of apolipoprotein E (ApoE) to the nanoparticle surface, which enables their recognition by lipoprotein receptors and uptake by liver cells. However, increasing evidence suggests that the tropism of LNPs can be altered by controlling lipid composition, physical and chemical properties, and acquired biological properties. This review discusses the mechanisms responsible for the liver tropism of LNPs as well as recent trends in modulating LNP tropism to extrahepatic organs. How ionizable lipids, helper lipids and sterols, PEG-lipids, LNP properties, and interaction with the protein corona can impact the organ tropism of LNPs as well as approaches for active and endogenous targeting of LNPs for organ- and cell-specific delivery are discussed. The challenges associated with organ- and cell-selective delivery of nucleic acids, such as delivery to functionally specific cell populations, endosomal release, species-specific translation, safety, repeated dosing, and clinical translation, are also described.
Related
- RING E3 ligase TRIM8 is structurally selective for UBE2N-mediated ubiquitination
- Computational Modeling of Vasculogenesis and Angiogenesis as Emergent Processes for the Design of Tissue Engineering Strategies
- Engineering morphology of tetrasulfide-incorporated mesoporous silica nanoparticles for enhanced mRNA delivery
- Rapid receptor internalization potentiates CD7-targeted lipid nanoparticles for efficient mRNA delivery to T cells and in vivo CAR T-cell engineering
- Robust Electrochemical Aptasensing of VEGF Based on Poly-adenine Mediated DNA Self-Assembly and Triple Labeling of Silver Nanoparticles.
BibTeX
@article{rachamala2026engineering,
title = {{Engineering Lipid Nanoparticles Beyond ApoE-Mediated Liver Tropism: Design Strategies for Extrahepatic and Organ-Selective Delivery}},
author = {Hari Krishnareddy Rachamala and Gianluca Medigovic and Sandeep Atla and Ramcharan Singh Angom},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms27219818},
url = {https://www.mdpi.com/1422-0067/27/21/9818},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Engineering Lipid Nanoparticles Beyond ApoE-Mediated Liver Tropism: Design Strategies for Extrahepatic and Organ-Selective Delivery
AU - Hari Krishnareddy Rachamala
AU - Gianluca Medigovic
AU - Sandeep Atla
AU - Ramcharan Singh Angom
PY - 2026
DA - 2026/11/01
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219818
UR - https://www.mdpi.com/1422-0067/27/21/9818
AB - Lipid nanoparticles (LNPs) have evolved into a significant delivery technology for nucleic acid therapies, including messenger RNA (mRNA), small interfering RNA (siRNA), and genome editing tools. Although LNPs have demonstrated therapeutic success, they display strong tropism to the liver when systemically delivered, thus restricting their use for targeted delivery to extrahepatic organs. The major factor responsible for the liver targeting of LNPs is the binding of apolipoprotein E (ApoE) to the nanoparticle surface, which enables their recognition by lipoprotein receptors and uptake by liver cells. However, increasing evidence suggests that the tropism of LNPs can be altered by controlling lipid composition, physical and chemical properties, and acquired biological properties. This review discusses the mechanisms responsible for the liver tropism of LNPs as well as recent trends in modulating LNP tropism to extrahepatic organs. How ionizable lipids, helper lipids and sterols, PEG-lipids, LNP properties, and interaction with the protein corona can impact the organ tropism of LNPs as well as approaches for active and endogenous targeting of LNPs for organ- and cell-specific delivery are discussed. The challenges associated with organ- and cell-selective delivery of nucleic acids, such as delivery to functionally specific cell populations, endosomal release, species-specific translation, safety, repeated dosing, and clinical translation, are also described.
SN - 1422-0067
ER -